Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.68 |
| ▸ | CYSLTR1 | Q9Y271 | 9/20 | 0.67 |
| ▸ | CYSLTR2 | Q9NS75 | 7/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.66 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7592907 | 0.99 | GPBAR1 (0.67) | GPBAR1CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL7592890 | 0.99 | GPBAR1 (0.67) | GPBAR1CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL8651391 | 0.90 | GPBAR1 (0.65) | GPBAR1CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL7592897 | 0.89 | GPBAR1 (0.64) | GPBAR1CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL8651401 | 0.87 | CYSLTR1 (0.65) | GPBAR1CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL7594868 | 0.86 | GPBAR1 (0.60) | GPBAR1CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL7594851 | 0.86 | GPBAR1 (0.60) | GPBAR1CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL7603712 | 0.86 | GPBAR1 (0.70) | GPBAR1CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL7594542 | 0.85 | GPBAR1 (0.59) | GPBAR1CYSLTR1CYSLTR2FFAR1AKR1B1 | |
| SCHEMBL7594522 | 0.85 | GPBAR1 (0.59) | GPBAR1CYSLTR1CYSLTR2FFAR1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737809-A4 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC (US) | 2007-10-17 | — | — | EP | claimed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | claimed |
| EP-1737809-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2007-01-03 | — | — | EP | claimed |
| US-20060004012-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. | 2006-01-05 | — | — | US | claimed |
| WO-2005086661-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2005-09-22 | — | — | WO | claimed |
| EP-0862557-B1 | SYMMETRICAL bis-HETEROARYLMETHOXYPHENYLALKYL CARBOXYLATES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LAB (US) | 2002-11-27 | — | — | EP | claimed |
| US-5795900-A | Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1998-08-18 | — | — | US | claimed |
| US-7816367-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7649110-B2 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1737809-A4 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1737809-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20060004012-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005086661-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-0862557-B1 | SYMMETRICAL bis-HETEROARYLMETHOXYPHENYLALKYL CARBOXYLATES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | ABBOTT LAB (US) | 2002-11-27 | — | — | EP | disclosed |
| US-5843968-A | Symmetrical bis-heteroarylmethoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1998-12-01 | — | — | US | disclosed |
| US-5795900-A | Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1998-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004012-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | GPBAR1 1014/4885CYSLTR1 2215/4885CYSLTR2 1559/4885 |
| US-20070142384-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | GPBAR1 1014/4885CYSLTR1 2215/4885CYSLTR2 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.